Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9849139 | 1.00 | HDAC1 (0.65) | HDAC1HDAC6ATMCTSSCTSK | |
| SCHEMBL31362607 | 0.90 | HDAC1 (0.61) | HDAC1HDAC6ATMCTSSCTSK | |
| SCHEMBL14270781 | 0.88 | HDAC1 (0.60) | HDAC1HDAC6ATMCTSSCTSK | |
| SCHEMBL5887330 | 0.88 | HDAC1 (0.65) | HDAC1HDAC6ATMALDH1A1THRB | |
| SCHEMBL9849273 | 0.88 | FPR2 (0.56) | HDAC1HDAC6CTSSCTSKKMT2A | |
| SCHEMBL502911 | 0.88 | HDAC1 (0.65) | HDAC1HDAC6ATMALDH1A1THRB | |
| SCHEMBL9849270 | 0.88 | FPR2 (0.56) | HDAC1HDAC6CTSSCTSKKMT2A | |
| SCHEMBL539217 | 0.87 | CTSS (0.67) | HDAC1HDAC6CTSSCTSKALDH1A1 | |
| SCHEMBL539218 | 0.87 | CTSS (0.67) | HDAC1HDAC6CTSSCTSKALDH1A1 | |
| SCHEMBL2706238 | 0.87 | CTSS (0.67) | HDAC1HDAC6CTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| EP-3426648-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HDAC1 98/4885HDAC6 1241/4885ATM 1453/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | HDAC1 98/4885HDAC6 1241/4885ATM 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.